Cancer Research Accelerated: Guardant Health and ConcertAI Launch Data-As-A-Service
Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, and ConcertAI, a top provider of oncology real-world evidence (RWD) data and AI-driven SaaS technology, have announced a new collaboration. This partnership offers biopharmaceutical companies access to the first-ever multi-modal real-world data (RWD) platform that combines comprehensive patient electronic medical record (EMR) data with detailed genomic and epigenomic tumor profiling information across all stages of cancer care.
Cancer is a highly complex disease, with a patient’s response to treatment influenced by various factors, including specific driver mutations, previous therapies, and acquired resistance. Understanding these complexities is critical for developing effective cancer therapies. In response to this challenge, Guardant Health and ConcertAI have entered into a collaboration to create a groundbreaking joint solution that integrates comprehensive real-world data (RWD) to support biopharmaceutical companies in accelerating cancer research and therapy development.
This collaboration offers access to a unique multi-modal real-world dataset that combines patient electronic medical record (EMR) data with both genomic and epigenomic tumor profiling information, spanning the entire continuum of cancer care. This integrated data solution provides essential clinical context, offering deep insights into disease biology, tumor evolution, and mechanisms of resistance. These insights are crucial for understanding the drivers behind cancer progression and resistance, and they can significantly inform clinical trial design, biomarker identification, and the development of targeted therapies.
Helmy Eltoukhy, co-CEO of Guardant Health, emphasized the importance of understanding the tumor from multiple dimensions to unlock the potential of precision medicine. He said, “Realizing the potential of precision medicine requires a comprehensive, multi-dimensional understanding of the tumor, the clinical environment, and the patient’s response to therapy. This partnership between Guardant and ConcertAI gives evidence and outcomes researchers access to extensive, robust data and AI-based modeling that can provide unprecedented insight into a patient’s cancer journey.”
The collaboration leverages Guardant Health’s advanced technologies and ConcertAI’s extensive data analytics capabilities. Together, they can offer biopharma collaborators an integrated solution that combines cutting-edge liquid biopsy platforms, artificial intelligence (AI) analytics, and precision oncology insights. The integrated platform will enable biopharma companies to gain a deeper understanding of tumor biology, particularly the complex interactions within the tumor and its environment, thereby accelerating the development of much-needed cancer therapies.
A key feature of this data offering is the inclusion of methylation data derived from Guardant Health’s Infinity smart liquid biopsy platform. The platform’s methylome panel is a powerful tool for identifying the unique methylation patterns of each tumor. Methylation, a process that influences gene expression, plays a significant role in cancer progression but has been largely unexplored in clinical development. By incorporating this dimension into the dataset, the partnership aims to provide new insights into how tumors evolve and respond to treatment.
Additionally, the data will cover the entire spectrum of cancer care, from early-stage disease monitoring to advanced cancer treatment. This includes genomic profiling for detecting residual disease and recurrence in early-stage cancer, as well as treatment selection and therapy response monitoring in advanced stages. This comprehensive approach ensures that the data is highly valuable for biopharma researchers throughout the entire cancer care continuum.
Jeff Elton, CEO of ConcertAI, highlighted the potential of the collaboration in advancing cancer therapy discovery. He stated, “By integrating ConcertAI’s extensive clinical dataset and enterprise AI with the new data on tumor methylation patterns enabled by Guardant Health’s innovative sequencing technology, we can partner with biopharma researchers to enable novel approaches to cancer therapy discovery, clinical study design, and innovative models for clinical development.” He further emphasized that providing biopharma collaborators with access to such deep and broad data would help accelerate the development of new therapies, particularly for patients with limited targeted therapy options.
While financial terms of the partnership were not disclosed, the collaboration represents a significant advancement in cancer research. By combining their respective strengths, Guardant Health and ConcertAI are setting a new standard for integrated cancer data solutions. Their shared vision is to make precision oncology more accessible and effective, ultimately improving patient outcomes and helping to bring new, life-saving therapies to market faster.
Guardant Health: A Leader in Real-World Data for Oncology
Guardant Health is a leading precision oncology company that has been transforming cancer care since its founding in 2012. The company offers a vast multimodal clinical-genomic database that integrates data from next-generation sequencing, demographics, cancer diagnoses, treatment and procedures, and pharmacy prescription data. This database spans over 60 solid tumor types and includes information on more than 450,000 unique patients across the entire care continuum. By analyzing this data, Guardant Health provides crucial insights into therapy response and resistance, supporting the development of targeted therapies, optimizing clinical trials, and enabling post-marketing studies.
Through its innovative blood and tissue tests, Guardant Health is helping to improve outcomes for patients at every stage of care. From early detection through screening to treatment selection for advanced , Guardant Health is at the forefront of precision oncology, providing the data and insights necessary to drive the next generation of cancer therapies.
